Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
Labcorp (LH) and Waters Corporation (WAT) partner to expand access to the FDA-approved BD Onclarity HPV Assay for cervical cancer screening, starting late 2026. The test supports all ASCCP guidelines and offers extended genotyping. Labcorp will provide testing through its nationwide network, aiming to address screening gaps and improve access for patients.
How this was made
The 30-second read
Why it matters
The partnership could drive incremental test volumes for both companies, but financial impact remains uncertain.
Market read
A new diagnostic partnership with modest upside potential for the involved firms.
What to watch
Potential regulatory or reimbursement hurdles could delay or limit test adoption.
Background
The announcement follows ongoing efforts to increase cervical cancer screening rates in the U.S.
Ticker impact
Labcorp announced a partnership to offer the FDA‑approved BD Onclarity HPV assay across its network starting late 2026.
likely modest upside as the partnership may boost test volumes.
The deal adds a new service line but lacks disclosed financial magnitude; impact depends on adoption rates.
Waters Corporation partnered with Labcorp to distribute its BD Onclarity HPV test nationwide beginning late 2026.
possible slight positive pressure as the partnership expands market reach.
No specific revenue figures disclosed; benefit hinges on test uptake.
Market effects
strengthens the diagnostics and laboratory services sector with a broader HPV testing offering.
U.S. healthcare providers may see improved access to cervical cancer screening.
limited to U.S. market; modest global relevance.
Counterpoint
Without clear revenue guidance, the partnership may not materially affect earnings.
Key entities
- CompanyLabcorp
Global laboratory services provider (NYSE: LH).
- CompanyWaters Corporation
Life sciences and diagnostics company (NYSE: WAT).
